Pfizer Corporation

Amgen Inc.

Edgewise Therapeutics, Inc.

Array Biopharma Inc.

Biogen Ma Inc.

West Services, Inc.

Edgewise Therapecutics, Inc.

Thomson Reuters Global Resources

Thomson Reuters Global Resources Unlimited Company

Astrazeneca Ab

Thomson Reuters Enterprise Centre Gmbh

Sunesis Pharmaceuticals, Inc.

Kevin Koch

Stephen T Schlachter

Kevin W Hunt

Alan Russell

Joseph P Lyssikatos

Chris Steele

Paul Winship

Andreas Peter Termin

John A Josey

Eli M Wallace

Gnanasambandam Kumaravel

Bin Ma

Brian T Hopkins

Anthony D Piscopio

Lei Zhang

Lihong Sun

Mark Anthony Dombroski

Timothy Raymond Chan

Hua Miao

Grace Uzoho

Allison L Marlow

T Brian Hurley

Grover Mundell

Robert L Dow

Gary R Schulte

Khalid Al-Kofahi

Craig Alan Larson

David Wayne DeMoss

Craig Larson

Marc Light

Joel Hurwitz

David Demoss

James F Blake

Steven Wade Andrews

Lawrence S Melvin, Jr

Michael Luzzio

Kevin Ronald Condroski

Rui Xu

George T Topalov

John Peter Fischer

Martha E Rodriguez

Jay Bradford Fell

Lawrence Alan Reiter

Hong Woon Yang

Shannon L Winski

Yvan Le Huerou

Sally Gut Ruggeri

Gregory F Miknis

Davin Fifield

Sandra E Russo-Rodriguez

Lisa A De Meese

Patrice A Lee

Conrad Hummel

Natalie Anne Hawryluk

Marc Justin Evanchik

Carlos Luis Del Rio

David Wayne Demoss

Brian T Hurley

The present disclosure generally relates to substituted quinolinone amide compounds or salts of Formula (I), (II-A), (IV), or (III) and pharmaceutical compositions thereof. The substituted quinolinone amide compounds or salts of Formula (I), (II-A), (IV), or (III) disclosed herein may be used to treat or prevent cardiac disease in an individual in need thereof.

Quinolinone amide compounds and uses thereof

Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

Pyridazinone compounds and uses thereof

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Biaryl inhibitors of Bruton's tyrosine kinase

Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.

Treatment of brain cancer

Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-&#x3b1;.

Biaryl inhibitors of Bruton'S tyrosine kinase

Biaryl inhibitors of bruton's tyrosine kinase

An exemplary method includes accessing a source document where the source document is associated with a citation and copying a selected portion of the source document. Then, in response to copying the selected portion, the method includes generating a referenced element where the referenced element consists of the selected portion and a hyperlink associated with the citation. Finally, the method includes accessing a destination document and inserting the referenced element into the destination document. An additional exemplary method further includes storing a copy of the referenced element in a memory of an access device. Another exemplary method includes annotating the destination document and generating an annotated destination document. Another exemplary method includes printing, within a single print session, the annotated destination document and the source document. Yet another exemplary method includes printing, within a single print session, a non-annotated destination document, the annotated destination document and the source document.

Systems, methods, software and interfaces for performing enhanced document processing and document outlining

For automated text processing, the inventors devised, among other things, an exemplary system that includes an entity tagger, an entity resolver, a text segment classifier, and a relationship extractor. The entity tagger receives an input text segment, and tags named entities with the segment as being a person, company, or place. The entity resolver accesses authority files, and associates the persons and companies named in the text segment with specific entries in the files. The text segment classifier determines whether the text segment includes a relationship event, such as job-change event or merger and acquisition event, and if an event is detected, the relationship extractor determines the event role of entities named in the segment. For example, the extractor determines for a merger and acquisition event, which named company was the acquirer and which was acquired.

Systems, methods, software and interfaces for entity extraction and resolution and tagging

Growing community of inventors

Boulder, CO, United States of America

Kevin Koch